Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Oratie Michiel van de Sande over vooruitgang sarcoomzorg
nov 2021 | Bot en wekedelentumoren